Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02117297
Title SCT Plus Immune Therapy in Average Risk AML/MDS
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York Medical College
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.